NO20073830L - Medikamenter for behandling eller forebygging av fibrotiske sykdommer - Google Patents

Medikamenter for behandling eller forebygging av fibrotiske sykdommer

Info

Publication number
NO20073830L
NO20073830L NO20073830A NO20073830A NO20073830L NO 20073830 L NO20073830 L NO 20073830L NO 20073830 A NO20073830 A NO 20073830A NO 20073830 A NO20073830 A NO 20073830A NO 20073830 L NO20073830 L NO 20073830L
Authority
NO
Norway
Prior art keywords
prevention
treatment
fibrotic diseases
medications
salts
Prior art date
Application number
NO20073830A
Other languages
English (en)
Inventor
Armin Heckel
Gerald Juergen Roth
Thorsten Lehmann-Lintz
John Edward Park
Nveed Chaudhary
Jorg Kley
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20073830L publication Critical patent/NO20073830L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av indolinoner med generelle formel (I), substituert i 6 stilling, hvor R1 til R6 og X er definert som i krav 1, isomerer og salter derav, spesielt fysiologisk akseptabele salter derav, som et medikament for forebygging eller behandling av spesifikke fibrotiske sykdommer. ?? ?? ?? ??
NO20073830A 2004-12-24 2007-07-23 Medikamenter for behandling eller forebygging av fibrotiske sykdommer NO20073830L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030769 2004-12-24
PCT/EP2005/057013 WO2006067175A1 (en) 2004-12-24 2005-12-21 Medicaments for the treatment or prevention of fibrotic diseases

Publications (1)

Publication Number Publication Date
NO20073830L true NO20073830L (no) 2007-07-23

Family

ID=35717457

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073830A NO20073830L (no) 2004-12-24 2007-07-23 Medikamenter for behandling eller forebygging av fibrotiske sykdommer

Country Status (26)

Country Link
US (3) US20060148883A1 (no)
EP (1) EP1835907B1 (no)
JP (1) JP5748386B2 (no)
KR (1) KR20070092305A (no)
CN (1) CN101087604B (no)
AR (1) AR052439A1 (no)
AT (1) ATE429222T1 (no)
AU (1) AU2005318136B2 (no)
BR (1) BRPI0519351A2 (no)
CA (1) CA2591089C (no)
DE (1) DE602005014145D1 (no)
DK (1) DK1835907T3 (no)
EA (1) EA200701181A1 (no)
ES (1) ES2326277T3 (no)
HR (1) HRP20090312T1 (no)
IL (1) IL184124A0 (no)
MX (1) MX2007007676A (no)
NO (1) NO20073830L (no)
PE (1) PE20061155A1 (no)
PL (1) PL1835907T3 (no)
PT (1) PT1835907E (no)
RS (1) RS50833B (no)
SI (1) SI1835907T1 (no)
TW (1) TW200637544A (no)
WO (1) WO2006067175A1 (no)
ZA (1) ZA200703600B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169936B2 (en) * 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) * 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
WO2008108238A1 (ja) * 2007-03-02 2008-09-12 Mitsui Chemicals, Inc. 不織布積層体
US8741890B2 (en) * 2007-11-15 2014-06-03 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
US20090131359A1 (en) * 2007-11-19 2009-05-21 Atamas Sergei P Antifibrotic therapy
ES2394239T3 (es) * 2008-01-25 2013-01-23 Boehringer Ingelheim International Gmbh Formas salinas de un derivado de 6-fluoro-1,2-dihidro-2-oxo-3H-indol-3-ilideno, procedimiento para su preparación y composiciones farmacéuticas que las contienen
CN102227237A (zh) * 2008-09-26 2011-10-26 国家健康与医学研究院 作为针对hcv感染的抗病毒治疗的靶标的宿主细胞激酶
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
US10450295B2 (en) 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763361B2 (en) * 1998-09-25 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PE20040701A1 (es) * 2002-07-23 2004-11-30 Boehringer Ingelheim Pharma Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos
US7169936B2 (en) * 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments

Also Published As

Publication number Publication date
EP1835907A1 (en) 2007-09-26
CN101087604A (zh) 2007-12-12
US20140128409A1 (en) 2014-05-08
ES2326277T3 (es) 2009-10-06
CN101087604B (zh) 2010-10-13
CA2591089A1 (en) 2006-06-29
JP2008525374A (ja) 2008-07-17
PE20061155A1 (es) 2006-12-16
AU2005318136A1 (en) 2006-06-29
AR052439A1 (es) 2007-03-21
BRPI0519351A2 (pt) 2009-01-20
EP1835907B1 (en) 2009-04-22
TW200637544A (en) 2006-11-01
IL184124A0 (en) 2007-10-31
JP5748386B2 (ja) 2015-07-15
ZA200703600B (en) 2008-07-30
PT1835907E (pt) 2009-06-16
WO2006067175A1 (en) 2006-06-29
US20120004202A1 (en) 2012-01-05
EA200701181A1 (ru) 2008-02-28
HRP20090312T1 (en) 2009-07-31
DK1835907T3 (da) 2009-08-03
US20060148883A1 (en) 2006-07-06
DE602005014145D1 (de) 2009-06-04
ATE429222T1 (de) 2009-05-15
AU2005318136B2 (en) 2012-02-09
CA2591089C (en) 2014-02-11
RS50833B (sr) 2010-08-31
SI1835907T1 (sl) 2009-10-31
PL1835907T3 (pl) 2009-08-31
MX2007007676A (es) 2007-08-14
KR20070092305A (ko) 2007-09-12

Similar Documents

Publication Publication Date Title
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
NO20065904L (no) Terapeutiske forbindelser
NO20072389L (no) Substituerte benzokinolizinderivater
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20082096L (no) Azaindol-2-karboksamidderivativer
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20074872L (no) Pyrazoler
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application